Authors

Peng Zhao, Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University
Qi Li, State Key Lab of Reproductive Medicine, Department of Pathology, Collaborative Innovation Center for Cancer Personalized Medicine, Cancer Center, Nanjing Medical University; Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing, University Medical SchoolFollow
Zhumei Shi, Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University
Charlie Li, Department of Environmental Toxicology, University of California-Davis
Lin Wang, State Key Lab of Reproductive Medicine, Department of Pathology, Collaborative Innovation Center for Cancer Personalized Medicine, Cancer Center, Nanjing Medical University
Xue Liu, State Key Lab of Reproductive Medicine, Department of Pathology, Collaborative Innovation Center for Cancer Personalized Medicine, Cancer Center, Nanjing Medical UniversityFollow
Chengfei Jiang, State Key Lab of Reproductive Medicine, Department of Pathology, Collaborative Innovation Center for Cancer Personalized Medicine, Cancer Center, Nanjing Medical University; Ninggao Personalized Medicine and Technology Innovation CenterFollow
Xu Qian, State Key Lab of Reproductive Medicine, Department of Pathology, Collaborative Innovation Center for Cancer Personalized Medicine, Cancer Center, Nanjing Medical University; Ninggao Personalized Medicine and Technology Innovation Center
Yongping You, Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University
Ning Liu, Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical UniversityFollow
Ling-Zhi Liu, Lab of Reproductive Medicine, Department of Pathology, Cancer Center, Nanjing Medical University, Nanjing, Jiangsu, China; Department of Pathology, Anatomy and Cell Biology, and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PennsylvaniaFollow
Lianshu Ding, Department of Neurosurgery, Huai'an First People's Hospital, Nanjing Medical University
Bing-Hua Jiang, State Key Lab of Reproductive Medicine, Department of Pathology, Collaborative Innovation Center for Cancer Personalized Medicine, Cancer Center, Nanjing Medical University; Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

10-13-2015

Comments

This article has been peer reviewed. It was published in: Oncotarget.

Volume 6, Issue 31, 2015, Pages 31901-31915.

The published version is available at DOI: 10.18632/oncotarget.5043

Copyright © 2015 The Authors

Abstract

BACKGROUND: Glioma accounts for the majority of primary malignant brain tumors in adults.

METHODS: Glioma specimens and normal brain tissues were analyzed for the expression levels of GSK-3β and p-GSK-3β (Ser9) by tissue microarray analysis (TMA) and Western blotting. Glioma cells over-expressing GSK-3β were used to analyze biological functions both in vitro and in vivo.

RESULTS: The levels of p-GSK-3β (Ser9), but not total GSK-3β, are significantly up-regulated in glioma tissues compared to normal tissues, and are significantly correlated with the glioma grades. Ectopic expression of GSK-3β decreased the phosphorylation levels of mTOR and p70S6K1; and inhibited β-catenin, HIF-1α and VEGF expression. Forced expression of GSK-3β in glioma cells significantly inhibited both tumor growth and angiogenesis in vivo.

CONCLUSIONS: These results reveal that GSK-3β regulates mTOR/p70S6K1 signaling pathway and inhibits glioma progression in vivo; its inactivation via p-GSK-3β (Ser9) is associated with glioma development, which is new mechanism that may be helpful in developing GSK-3β-based treatment of glioma in the future.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

PubMed ID

26388612

Share

COinS